RA Capital Management sells $9.13M in Lenz Therapeutics shares

RA Capital Management, L.P., a director and 10% owner of LENZ Therapeutics, Inc., announced on October 29, 2026, the sale of common stock amounting to approximately $9,134,778. The company owned 2,718,684 shares, which were sold in three separate transactions at a weighted average price of $3.36 per share, ranging from $3.16 to $3.58.

The largest transaction was the sale of 2,159,516 shares, totaling about $7,256,094. Following the sale, RA Capital Management, L.P. indirectly owned 1,159,823 shares through RA Capital Healthcare Fund, L.P., 242,757 shares through RA Capital Nexus Fund II, L.P., and 57,559 shares through a separately managed account. LENZ shares had declined by nearly 90% over the past year, currently trading near its 52-week low of $2.80.

Despite the stock's decline, the presbyopia eye drop, VIZZ, demonstrated growth, with revenue increasing by more than 50% sequentially to $2.6 million and prescriptions rising to 38,000. Lenz Therapeutics adjusted its price target from $38 to $16, with a Buy rating maintained.